Erratum: Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy (Cancer DOI: 10.1002/cncr.27980);Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: A decision analysis

Cancer

Volumn 119, Issue 10, 2013, Pages 1808-1815

  Lester Coll, Nataniel H ^a   Goldhaber, Samuel Z ^b   Sher, David J ^c   D'Amico, Anthony V ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cardiovascular disease; decision analysis; hormonal therapy; prostate cancer; radiation therapy

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GOSERELIN; TRIPTORELIN;

ADULT; AGE; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; IMPOTENCE; INTESTINE FUNCTION DISORDER; LIFE EXPECTANCY; LONG TERM CARE; MALE; MARKOV DECISION ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; SALVAGE THERAPY; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; URINE INCONTINENCE;

EID: 84877580056     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28073     Document Type: Erratum

References (31)

1. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360: 2516-2527.
2. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010; 11: 1066-1073.
3. Crook J, Ludgate C, Malone S, et al. Final report of multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 73: 327-333.
4. D'Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW,. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299: 289-295.
5. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011; 12: 451-459.
6. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997; 37: 247-252.
7. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997; 15: 1013-1021.
8. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009; 373: 301-308.
9. Keating NL, O'Malley AJ, Freedland SJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010; 102: 39-46.
10. Nanda A, Chen M-H, Braccioforte MH, Moran BJ, D'Amico AV,. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009; 302: 866-873.
11. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR,. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol. 2011; 29: 3510-3516.
12. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS,. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007; 110: 1493-1500.
13. Smith MR, Klotz L, van der Meulen E, Colli E, Tanko LB,. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol. 2011; 186: 1835-1842.
14. Tsai HK, D'Amico AV, Sadetsky N, Chen M-H, Carroll PR,. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99: 1516-1524.
15. Nguyen PL, Je Y, Schutz Y, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011; 306: 2359-2366.
16. Vasan RS, Sullivan LM, Wilson PWF, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med. 2005; 142: 393-402.
17. Naimark DMJ, Bott M, Krahn M,. The half-cycle correction explained: 2 alternative pedagogical approaches. Med Decis Making. 2008; 28: 706-712.
18. D'Amico AV, Chen M-H, Renshaw AA, Loffredo M, Kantoff PW,. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys. 2009; 75: 10-15.
19. Kaku H, Saika T, Tsushima T, et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate. 2006; 66: 439-444.
20. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 1591-1597.
21. Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation. 1998; 98: 1860-1868.
22. Altekruse SF, Kosary CL, Krapcho M, et al., eds. Trends in SEER Incidence and US Mortality. SEER Cancer Statistics Review 1975-2007 [based on November 2009 SEER data submission, posted to the SEER website 2010]. Bethesda, MD: National Cancer Institute; 2009. Available at: http://seeer.cancer.gov/csr/ 19975-2007/. [Accessed October 28, 2011.]
23. Keenan NL, Shaw KM,. Coronary heart disease and stroke deaths-United States, 2006. MMWR. 2011; 60 (suppl): 62-66.
24. Xu J, Kochanek KD, Murphy SL, et al. Deaths: final data for 2007. Natl Vital Stat Rep. 2010; 58: 1-136.
25. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010; 304: 2373-2380.
26. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM,. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005; 43: 347-355.
27. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L,. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011; 124: 146-153.
28. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294: 1233-1239.
29. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26: 585-591.
30. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978.
31. Nguyen PL, Chen MH, Goldhaber SZ, et al. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer. 2011; 117: 406-413.